by Erin | Jul 28, 2025 | Blog
Specialty doctors are concerned about the harmful impacts of prescription drug affordability boards, a white paper commissioned by the Value of Care Coalition recently found. The survey asked endocrinologists, rheumatologists and HIV specialists for their opinions on...
by Erin | Jul 16, 2025 | Blog
While some states continue to struggle with the operations of Prescription Drug Affordability Boards (PDABs), others are saying “no” to upper payment limits altogether. This year, the governors of Virginia and Nevada vetoed legislation that would have either...
by Erin | Jun 17, 2025 | Blog
In recent years, prescription drug affordability boards (PDABs) have struggled as they implement their cost review and price-setting policies. Now, some states are attempting to cut out these regulatory processes entirely. Instead of creating new PDABs, some states...
by Erin | May 16, 2025 | Blog
The March meeting of the Maryland Prescription Drug Affordability Board (PDAB) ignited significant concerns among a broad group of patient, physician, pharmacist and caregiver organizations. Recent legislation requires the PDAB to conduct an analysis on the impact of...
by Erin | Apr 22, 2025 | Blog
An oft-repeated talking point for proponents of prescription drug affordability boards is that capping the top-line price of medications will result in lower premiums and out-of-pocket spending by patients. But a new report from the Partnership to Fight Chronic...
by Erin | Apr 9, 2025 | Blog
A new cost-benefit analysis from Colorado’s Department of Regulatory Agencies reveals a concerning finding: the government doesn’t know, and can’t predict, what the economic benefits of prescription drug affordability board policies might be. The analysis,...
